Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.94 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.94 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.94 |
| ▸ | MEN1 | O00255 | 2/20 | 0.94 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.94 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.94 |
| ▸ | LMNA | P02545 | 1/20 | 0.94 |
| ▸ | HTR4 | Q13639 | 4/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29385613 | 1.00 | CYP2C9 (0.94) | CYP2C9PMP22NPSR1MEN1CYP3A4 | |
| SCHEMBL7302574 | 0.99 | CYP2C9 (0.95) | CYP2C9PMP22NPSR1MEN1CYP3A4 | |
| Hydrochloric Acid SCHEMBL7295175 | 0.99 | CYP2C9 (0.92) | CYP2C9PMP22NPSR1MEN1CYP3A4 | |
| Maleic Acid SCHEMBL7302318 | 0.95 | CYP2C9 (0.86) | CYP2C9PMP22NPSR1MEN1CYP3A4 | |
| Fumaric Acid SCHEMBL7302323 | 0.95 | CYP2C9 (0.86) | CYP2C9PMP22NPSR1MEN1CYP3A4 | |
| SCHEMBL14908005 | 0.91 | CYP2C9 (0.79) | CYP2C9PMP22NPSR1MEN1CYP3A4 | |
| SCHEMBL7292069 | 0.91 | CYP2C9 (0.78) | CYP2C9PMP22NPSR1MEN1CYP3A4 | |
| SCHEMBL7300823 | 0.88 | CYP2C9 (0.74) | CYP2C9PMP22NPSR1MEN1CYP3A4 | |
| SCHEMBL16504002 | 0.82 | CYP2C9 (0.66) | CYP2C9PMP22NPSR1MEN1CYP3A4 | |
| SCHEMBL7302280 | 0.82 | CYP2C9 (0.66) | CYP2C9PMP22NPSR1MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8829028-B2 | 5-HT4 receptor antagonists for the treatment of heart failure | SERODUS AS (NO) | 2014-09-09 | — | — | US | claimed |
| EP-1503764-B1 | 5-HT4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF HEART FAILURE | SERODUS AS (NO) | 2010-01-06 | — | — | EP | claimed |
| US-20090169545-A1 | 5-HT4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF HEART FAILURE | SERODUS AS (NO) | 2009-07-02 | — | — | US | claimed |
| US-20060094715-A1 | 5-Ht4 receptor antagonists for the treatment of heart failure | SERODUS AS (NO) | 2006-05-04 | — | — | US | claimed |
| EP-1503764-A1 | 5-HT4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF HEART FAILURE | MEDINNOVA AS (NO) | 2005-02-09 | — | — | EP | claimed |
| WO-2003097065-A1 | 5-HT4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF HEART FAILURE | MEDINNOVA AS (NO) | 2003-11-27 | — | — | WO | claimed |
| EP-0546593-B1 | Multi-layered compositions containing histamine or serotonin antagonists | GLAXO GROUP LTD (GB) | 1997-09-03 | — | — | EP | claimed |
| EP-0501322-B1 | 3-Piperidinylmethylcarboxylate substituted indoles | GLAXO GROUP LTD (GB) | 1996-09-04 | — | — | EP | claimed |
| US-5425950-A | Antiserotonine agent | GLAXO GROUP LIMITED (GB) | 1995-06-20 | — | — | US | claimed |
| WO-1993014745-A1 | USE OF 5-HT4 RECEPTOR ANTAGONISTS AS MEDICAMENTS FOR TREATING MIGRAINE | SMITHKLINE BEECHAM PLC (GB) | 1993-08-05 | — | — | WO | claimed |
| EP-0546593-A1 | Multi-layered compositions containing histamine or serotonin antagonists | GLAXO GROUP LIMITED (GB) | 1993-06-16 | — | — | EP | claimed |
| WO-1992014727-A1 | 3-PIPERIDINYLMETHYLCARBOXYLATE SUBSTITUTED INDOLES | GLAXO GROUP LIMITED (GB) | 1992-09-03 | — | — | WO | claimed |
| EP-0501322-A1 | 3-Piperidinylmethylcarboxylate substituted indoles | GLAXO GROUP LIMITED (GB) | 1992-09-02 | — | — | EP | claimed |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| US-10426773-B2 | Systems pharmacology for treating ocular disorders | CASE WESTERN UNIVERSITY (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190099420-A1 | SYSTEMS PHARMACOLOGY FOR TREATING OCULAR DISORDERS | CASE WESTERN UNIVERSITY | 2019-04-04 | — | — | US | disclosed |
| WO-1993014745-A1 | USE OF 5-HT4 RECEPTOR ANTAGONISTS AS MEDICAMENTS FOR TREATING MIGRAINE | SMITHKLINE BEECHAM PLC (GB) | 1993-08-05 | — | — | WO | disclosed |
| EP-0546593-A1 | Multi-layered compositions containing histamine or serotonin antagonists | GLAXO GROUP LIMITED (GB) | 1993-06-16 | — | — | EP | disclosed |
| WO-1992014727-A1 | 3-PIPERIDINYLMETHYLCARBOXYLATE SUBSTITUTED INDOLES | GLAXO GROUP LIMITED (GB) | 1992-09-03 | — | — | WO | disclosed |
| EP-0501322-A1 | 3-Piperidinylmethylcarboxylate substituted indoles | GLAXO GROUP LIMITED (GB) | 1992-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10426773-B2 | Systems pharmacology for treating ocular disorders | GRK1, MTNR1A, MTNR1B | CYP2C9 2438/4885PMP22 2636/4885NPSR1 89/4885 |
| US-20190099420-A1 | SYSTEMS PHARMACOLOGY FOR TREATING OCULAR DISORDERS | GRK1, MTNR1A, MTNR1B | CYP2C9 2438/4885PMP22 2636/4885NPSR1 89/4885 |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, TXNRD2, TXNRD1 | CYP2C9 4871/4885PMP22 2259/4885NPSR1 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.